Aditxt, Inc. - Common Stock (ADTX)
0.0044
+0.00 (0.00%)
NASDAQ· Last Trade: Jun 17th, 7:48 PM EDT
Detailed Quote
| Previous Close | - |
|---|---|
| Open | - |
| Bid | 0.0070 |
| Ask | 0.0071 |
| Day's Range | 0.0041 - 0.0089 |
| 52 Week Range | 0.0041 - 53,451.08 |
| Volume | 1,411,528,991 |
| Market Cap | 196.74K |
| PE Ratio (TTM) | -0.0000 |
| EPS (TTM) | -560.4 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 249,312,600 |
Chart
About Aditxt, Inc. - Common Stock (ADTX)
Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance. The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management. Read More
News & Press Releases
Which stocks are moving after the closing bell on Wednesday?chartmill.com
Via Chartmill · June 17, 2026
Top movers in Wednesday's sessionchartmill.com
Via Chartmill · June 17, 2026
Most active stocks in Wednesday's sessionchartmill.com
Via Chartmill · June 17, 2026
Which stocks have an unusual volume on Wednesday?chartmill.com
Via Chartmill · June 17, 2026
These stocks are moving in today's sessionchartmill.com
Via Chartmill · June 17, 2026
Gapping stocks in Wednesday's sessionchartmill.com
Via Chartmill · June 17, 2026
Discover the top movers in Wednesday's pre-market session.chartmill.com
Via Chartmill · June 17, 2026
Curious about the most active stocks on Tuesday?chartmill.com
Via Chartmill · June 16, 2026
These stocks have an unusual volume in today's sessionchartmill.com
Via Chartmill · June 16, 2026
Discover the most active stocks in Monday's session.chartmill.com
Via Chartmill · June 15, 2026
Get insights into the top gainers and losers of Friday's after-hours session.chartmill.com
Via Chartmill · June 12, 2026
Friday's session: most active stockschartmill.com
Via Chartmill · June 12, 2026
These stocks that are showing activity before the opening bell on Friday.chartmill.com
Via Chartmill · June 12, 2026
ADM Endeavors (OTCQB: ADMQ) continues executing a growth strategy focused on strengthening its balance sheet, expanding manufacturing capacity, and growing its presence in the U.S. apparel and branded merchandise market.
Via AB Newswire · June 11, 2026
Here are the top movers in Wednesday's session.chartmill.com
Via Chartmill · June 10, 2026
Check out the stocks that are attracting the most attention and driving market activity.chartmill.com
Via Chartmill · June 10, 2026
Top stock movements in today's session.chartmill.com
Via Chartmill · June 10, 2026
Wednesday's session: gap up and gap down stockschartmill.com
Via Chartmill · June 10, 2026
Wednesday's pre-market session: top gainers and loserschartmill.com
Via Chartmill · June 10, 2026
Tuesday's session: top gainers and loserschartmill.com
Via Chartmill · June 9, 2026
Which stocks are most active on Tuesday?chartmill.com
Via Chartmill · June 9, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · June 9, 2026
Which stocks are gapping on Tuesday?chartmill.com
Via Chartmill · June 9, 2026
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a qualified acquisition corp and Ignite Proteomics, LLC (“Ignite”, or “Ignite Proteomics”), a functional proteomics company and 100%-owned subsidiary of Aditxt, today announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement.
By Aditxt, Inc. · Via Business Wire · June 9, 2026
Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”) a subsidiary of Aditxt, Inc. (NASDAQ: ADTX), today announced the launch of a prospective oncology registry enrolling up to 10,000 patients. The registry is designed to pair Ignite’s CLIA-certified Reverse Phase Protein Array (“RPPA”) platform with structured clinical outcomes tracking to evaluate the real-world utility of functional proteomics in cancer therapy selection.
By Ignite Proteomics, LLC · Via Business Wire · June 8, 2026